{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:06:29Z","timestamp":1782475589787,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011238","name":"Lions Clubs International Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008556","name":"Paul MacKall and Evanina Bell MacKall Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ajo.2014.07.003","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T15:30:19Z","timestamp":1405438219000},"page":"831-837.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib"],"prefix":"10.1016","volume":"158","author":[{"given":"Christina H.","family":"Choe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A.","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivor","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi K.","family":"Amaravadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ajo.2014.07.003_bib1","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00268-010-0903-8","article-title":"Outcomes for lymph node-positive cutaneous melanoma over two decades","volume":"35","author":"Martinez","year":"2011","journal-title":"World J Surg"},{"issue":"6892","key":"10.1016\/j.ajo.2014.07.003_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ajo.2014.07.003_bib3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ajo.2014.07.003_bib4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ajo.2014.07.003_bib5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ajo.2014.07.003_bib6","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ajo.2014.07.003_bib7","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1345\/aph.1Q363","article-title":"Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma","volume":"45","author":"Heakal","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"11","key":"10.1016\/j.ajo.2014.07.003_bib8","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ophtha.2003.05.004","article-title":"Metastatic melanoma in the eye and orbit","volume":"110","author":"Zografos","year":"2003","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2014.07.003_bib9","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.ajo.2014.07.003_bib10","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMc1111672","article-title":"Vemurafenib for melanoma metastases to the brain","volume":"365","author":"Rochet","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ajo.2014.07.003_bib11","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s00417-003-0787-5","article-title":"Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up","volume":"241","author":"Aisenbrey","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2014.07.003_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/archderm.1978.01640150075022","article-title":"Uveitis, poliosis, hypomelanosis, and alopecia in a patient with malignant melanoma","volume":"114","author":"Sober","year":"1978","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.ajo.2014.07.003_bib13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ophtha.2008.12.004","article-title":"Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma","volume":"116","author":"Yeh","year":"2009","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1016\/j.ajo.2014.07.003_bib14","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ajo.2014.07.003_bib15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/jop.2009.0060","article-title":"PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion","volume":"25","author":"Huang","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.ajo.2014.07.003_bib16","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ajo.2014.07.003_bib17","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/1078-0432.CCR-09-1920","article-title":"A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer","volume":"16","author":"Haura","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"7287","key":"10.1016\/j.ajo.2014.07.003_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"issue":"7287","key":"10.1016\/j.ajo.2014.07.003_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ajo.2014.07.003_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.ajo.2014.07.003_bib21","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMc1108651","article-title":"Vemurafenib in melanoma with BRAF V600E mutation","volume":"365","author":"Dalle","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ajo.2014.07.003_bib22","first-page":"475","article-title":"Side effects of systemic oncological therapies in dermatology","volume":"10","author":"Zimmer","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"10.1016\/j.ajo.2014.07.003_bib23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.ajo.2014.07.003_bib24","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00002371-200411000-00008","article-title":"Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis","volume":"27","author":"Robinson","year":"2004","journal-title":"J Immunother"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939414003948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939414003948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:40:10Z","timestamp":1762080010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939414003948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0002939414003948"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2014.07.003","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2014.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}